Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529399 · ClinicalTrials.gov registry record · Phase 2
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT00529399 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 145 participants.
The verdict
NCT00529399, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes mellitus (T1DM).
Interventions
- DRUG GAD-Alum
- DRUG GAD-Alum and Aluminum hydroxide
- DRUG Aluminum hydroxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529399
The ClinicalTrials.gov registry entry for NCT00529399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GAD-Alum is the first listed.
NCT00529399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529399 about?
NCT00529399 is a clinical study titled "Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects". The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes mellitus (T1DM).
What is the current status of trial NCT00529399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2009-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00529399?
The interventions under investigation include: GAD-Alum (DRUG), GAD-Alum and Aluminum hydroxide (DRUG), Aluminum hydroxide (DRUG).
Who is sponsoring clinical trial NCT00529399?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.